Clinical Trials Logo
  1. Home
  2. Neoplasms Pancreatic
  3. NCT04161417

Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

Neoplasms Pancreatic Clinical Trial

Official title:
Precision-Panc Master Protocol: Personalising Treatment For Pancreatic Cancer

Clinical Trial Summary

The Precision-Panc Master Protocol is a "portal" protocol for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Studies) examining different treatment regimens and/or biomarker development. Eligible patients will undergo tumour biopsy and blood collection prospectively for molecular profiling at a central laboratory and the results may be used to inform enrolment to PRIMUS studies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04161417
Study type Interventional
Source University of Glasgow
Contact Judith Dixon-Hughes
Phone 01413302718
Email judith.dixon@glasgow.ac.uk
Status Recruiting
Phase N/A
Start date November 28, 2017
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01313416 - Gemcitabine and CT-011 for Resected Pancreatic Cancer Phase 2
Completed NCT05547074 - A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Completed NCT02973217 - Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Recruiting NCT04151277 - PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer Phase 2
Terminated NCT03187587 - Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Terminated NCT04176952 - PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer Phase 2
Recruiting NCT05669482 - Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2
Completed NCT03535727 - A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04566614 - Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
Completed NCT06118125 - Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2